Orange Book product · Brand (NDA)
ZELBORAF
VEMURAFENIB
At a glance
Aug 17, 2011
Approved
Brand (NDA)
Application
Not listed
TE code
7
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 17, 2011
15 yr 1 mo ago
Today
Patent 8143271 expires
Listed drug substance patent expiration.
Jun 21, 2026
in 2 d
Patent 8470818 expires
Listed method-of-use patent (U-2164) expiration.
Aug 02, 2026
in 1 mo
Patent 8470818 expires
Listed method-of-use patent (U-1418) expiration.
Aug 02, 2026
in 1 mo
Patent 7504509 expires
Listed drug substance patent expiration.
Oct 22, 2026
in 4 mo
Patent 7863288 expires
Listed drug substance patent expiration.
Jun 20, 2029
in 3 yr 1 mo
Patent 8741920 expires
Listed drug substance patent expiration.
Jul 27, 2030
in 4 yr 2 mo
Patent 9447089 expires
Listed drug product patent expiration.
Jun 06, 2032
in 6 yr 1 mo
Pharmaceutical detail
Active ingredient
VEMURAFENIB
Strength
240MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
NDA 202429
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8143271 | Jun 21, 2026 | in 2 d | SubstanceProduct |
| 8470818 | Aug 02, 2026 | in 1 mo | U-2164 |
| 8470818 | Aug 02, 2026 | in 1 mo | U-1418 |
| 7504509 | Oct 22, 2026 | in 4 mo | SubstanceProduct |
| 7863288 | Jun 20, 2029 | in 3 yr 1 mo | SubstanceProduct |
| 8741920 | Jul 27, 2030 | in 4 yr 2 mo | SubstanceProduct |
| 9447089 | Jun 06, 2032 | in 6 yr 1 mo | Product |
